The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 469 participants.

Also called NCT01106625

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 469 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01106625
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Belgium, France, Guatemala, Hungary, Israel, Mexico, Puerto Rico, Russia, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01106625. Randomized; triple masking; primary purpose treatment. Start 2010-05 (registry gives no type); primary completion 2011-09 (actual). Results posted on 2013-05-29.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea)
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Canagliflozin
Intervention (Drug)
Placebo
Intervention (Drug)
Metformin
Intervention (Drug)
Sulphonylruea
Lead sponsor
Janssen Research & Development, LLC (class: industry)

Record details

Record id
cardio:ct-nct01106625
Content hash
8aeee36fdb4aa800c6f0911542d14995728e97babce38240ad036e73629b17d3